Evaluation of nanoparticle immunotoxicity

Nature Nanotechnology

Volumn 4, Issue 7, 2009, Pages 411-414

  Dobrovolskaia, Marina A ^a   Germolec, Dori R ^b   Weaver, James L ^c  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NANOPARTICLES;

CURRENT TEST; EVALUATION METHODS; IMMUNE RESPONSE; IMMUNOTOXICITY; MARYLAND; NATIONAL CANCER INSTITUTE; PHARMACEUTICAL INDUSTRY; REGULATORY AGENCIES;

DRUG DELIVERY;

ANTINEOPLASTIC AGENT; ENDOTOXIN; IMMUNOSUPPRESSIVE AGENT; NANOMATERIAL; NANOPARTICLE; POLYGLACTIN; PYROGEN;

BLOOD COMPATIBILITY; COLONY FORMING UNIT GM; CYTOKINE RELEASE; DRUG CONTAMINATION; DRUG DELIVERY SYSTEM; DRUG LEGISLATION; DRUG SURVEILLANCE PROGRAM; FEVER; FLUORESCENCE; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTOXICITY; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; LIMULUS LYSATE TEST; LOCAL LYMPH NODE ASSAY; LUMINESCENCE; MOLECULAR INTERACTION; NANOTOXICOLOGY; NONHUMAN; PARTICLE SIZE; PHAGOCYTOSIS; PLAQUE FORMING CELL; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; SHORT SURVEY; TOXICITY TESTING; TURBIDITY;

EID: 67651205441     PISSN: 17483387     EISSN: 17483395     Source Type: Journal    
DOI: 10.1038/nnano.2009.175     Document Type: Short Survey

References (15)

1. US Food and Drug Administration Report of the FDA Nanotechnology Task Force (FDA, 2007); available at: .
2. European Medicines Agency Refection Paper on Nanotechnology-Based Medicinal Products for Human Use (EMEA, 2006); available at .
3. http://ncl.cancer.gov/nanoparticle-immunotoxicity-workshop.asp.
4. Vallhov, H. et al. Te importance of an endotoxin-free environment during the production of nanoparticles used in medical applications. Nano Lett. 6, 1682-1686 (2006).
5. Dean, J. H. Issues with introducing new immunotoxicology methods into the safety assessment of pharmaceuticals Toxicology 119, 95-101 (1997).
6. Dobrovolskaia, M. A. & McNeil, S. E. Immunological properties of engineered nanomaterials. Nature Nanotech. 2, 469-478 (2007).
7. Weaver, J. L. et al. Evaluation of a lymph node proliferation assay for its ability to detect pharmaceuticals with potential to cause immune-mediated drug reactions. J. Immunotoxicol. 2, 11-20 (2005).
8. Reddy, S. T. et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nature Biotechnol. 25, 1159-1164 (2007).
9. Manolova, V. et al. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38, 1404-1413 (2008).
10. Moghimi, S. M. & Szebeni, J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid. Res. 42, 463-478 (2003).
11. Pessina, A. et al. Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. Toxicol. Sci. 75, 355-367 (2003).
12. http://www.ich.org/cache/compo/502-272-1.html#S8.
13. US Food and Drug Administration Immunotoxicology Evaluation of Investigational New Drugs (FDA, 2002); available at .
14. http://www.ich.org/cache/compo/502-272-1.html#S6.
15. Fifs, T. et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 173, 3148-3154 (2004).